Cancer stem cells in acute lymphoblastic leukemia

Azadeh Anbarlou, A. Atashi, M. A. Rahnama, M. Soleimani, S. Kaviani
{"title":"Cancer stem cells in acute lymphoblastic leukemia","authors":"Azadeh Anbarlou, A. Atashi, M. A. Rahnama, M. Soleimani, S. Kaviani","doi":"10.14800/SCTI.783","DOIUrl":null,"url":null,"abstract":"Different models were suggested for cancer development. One of them is cancer stem cell model. In this model, Invasion, relapse and resistance to anti-cancer drugs were seen in cancerous cells are related to these cells. Recently, weobserved that some of population in T-Acute lymphoblastic leukemia cell line display cancer stem cell properties. These cells were detected by CD133 marker. In vitro transwell assay showed that CD133 + Jurkat cells were more invasive than CD133 - Jurkat cells and also gene expression analysis confirmed CD133 + Jurkat cells expressed MMP9 gene in high levels. After treatment of CD133 + cells with doxorubicin, Annexin-PI staining showed that these cells have high resistance to chemotherapy drug. We demonstrated chemotherapy resistance may be because of up regulation of ABCG2 gene. In addition, CD133 + cells had unrestricted proliferation potential and were able to differentiate to cells with low growth potential (CD133 - ). Altogether; we demonstrated that CD133 could be as a marker to recognize cancer stem cells in Jurkat cell line.","PeriodicalId":90974,"journal":{"name":"Stem cell and translational investigation","volume":"2 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2015-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stem cell and translational investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14800/SCTI.783","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Different models were suggested for cancer development. One of them is cancer stem cell model. In this model, Invasion, relapse and resistance to anti-cancer drugs were seen in cancerous cells are related to these cells. Recently, weobserved that some of population in T-Acute lymphoblastic leukemia cell line display cancer stem cell properties. These cells were detected by CD133 marker. In vitro transwell assay showed that CD133 + Jurkat cells were more invasive than CD133 - Jurkat cells and also gene expression analysis confirmed CD133 + Jurkat cells expressed MMP9 gene in high levels. After treatment of CD133 + cells with doxorubicin, Annexin-PI staining showed that these cells have high resistance to chemotherapy drug. We demonstrated chemotherapy resistance may be because of up regulation of ABCG2 gene. In addition, CD133 + cells had unrestricted proliferation potential and were able to differentiate to cells with low growth potential (CD133 - ). Altogether; we demonstrated that CD133 could be as a marker to recognize cancer stem cells in Jurkat cell line.
急性淋巴细胞白血病中的肿瘤干细胞
人们提出了不同的癌症发展模型。其中之一是癌症干细胞模型。在这个模型中,癌细胞的侵袭、复发和对抗癌药物的耐药都与这些细胞有关。最近,我们观察到t -急性淋巴母细胞白血病细胞系的一些群体表现出癌症干细胞的特性。这些细胞用CD133标记物检测。体外transwell实验显示CD133 + Jurkat细胞比CD133 - Jurkat细胞侵袭性更强,基因表达分析证实CD133 + Jurkat细胞高水平表达MMP9基因。CD133 +细胞经多柔比星处理后,Annexin-PI染色显示这些细胞对化疗药物具有高耐药性。我们证明化疗耐药可能是由于ABCG2基因的上调。此外,CD133 +细胞具有不受限制的增殖潜能,并能够分化为低生长潜能的细胞(CD133 -)。完全;我们证明CD133可以作为识别Jurkat细胞系中癌症干细胞的标记物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信